person · Reporting owner

Godshall Douglas Evan

Disclosed activity across 3 companies

Tapewire entity: 90381
SEC CIK: 0001404227

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
IMMUNIC, INC.VTL · Entity 6306	Director	September 19, 2018	September 21, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

IMMUNIC, INC.

Report date September 19, 2018 · Filed September 21, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2018-09-19 transaction · row 1 1 source row Row 1 · 2018-09-19 · Sale · Disposed 69,375 · Balance 0 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.34 to $0.35. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (1) to this Form 4.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.34 to $0.35. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (1) to this Form 4.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

EyePoint, Inc.

Report date June 22, 2021 · Filed June 23, 2021

Section 16 reporting ended · disclosed 2021-06-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	8,016	Reported balance After 2021-06-22 transaction · row 1 1 source row Row 1 · 2021-06-22 · Exercise / conversion · Acquired 2,500 · Balance 8,016
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2021-06-22 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-06-22 · Exercise / conversion · Acquired 2,500 · Balance 0 F1: The grants were approved by the Compensation Committee on February 9, 2021, subject to stockholder approval of an amendment to increase the number of shares in the Company's 2016 Plan. The shareholders approved the amendment on June 22, 2021. F2: The Restricted Stock grant vested immediately upon Mr. Godshall's departure from the Board on June 22, 2021.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.13 · Expires 2023-06-22	Direct	11,000	Reported balance After 2021-06-22 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-06-22 · Grant · Acquired 11,000 · Balance 11,000 F1: The grants were approved by the Compensation Committee on February 9, 2021, subject to stockholder approval of an amendment to increase the number of shares in the Company's 2016 Plan. The shareholders approved the amendment on June 22, 2021. F3: The option to purchase vested immediately upon Mr. Godshall's departure from the Board on June 22, 2021.

Filing footnotes · ownership attribution and instrument terms

F1: The grants were approved by the Compensation Committee on February 9, 2021, subject to stockholder approval of an amendment to increase the number of shares in the Company's 2016 Plan. The shareholders approved the amendment on June 22, 2021.

F2: The Restricted Stock grant vested immediately upon Mr. Godshall's departure from the Board on June 22, 2021.

F3: The option to purchase vested immediately upon Mr. Godshall's departure from the Board on June 22, 2021.

Shockwave Medical, Inc.

Report date May 31, 2024 · Filed May 31, 2024

Section 16 reporting ended · disclosed 2024-05-31. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2024-05-31 transaction · row 1 1 source row Row 1 · 2024-05-31 · Disposition to issuer · Disposed 151,629 · Balance 0 F1: This Form 4 reports the disposition of securities pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 4, 2024, by and among the Issuer, Johnson & Johnson ("J&J"), and Sweep Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of the effective time of the Merger (the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. As a result of the Merger, at the Effective Time, each outstanding share of common stock, par value $0.001 per share, of the Issuer ("Common Stock") outstanding immediately prior to the Effective Time (excluding Excluded Shares and any Dissenting Company Shares, each as defined in the Merger Agreement) was automatically converted into the right to receive $335.00 in cash (the "Merger Consideration"), F2: (Continued from Footnote 1) without interest and less any applicable withholding taxes. Additionally, pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time and (ii) the Merger Consideration.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.42 · Expires 2027-05-09	Direct	Reported balance After 2024-05-31 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-05-31 · Disposition to issuer · Disposed 294,799 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price that was less than the Merger Consideration, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2029-03-06	Direct	Reported balance After 2024-05-31 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-05-31 · Disposition to issuer · Disposed 81,967 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price that was less than the Merger Consideration, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.
Performance Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2024-05-31 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-05-31 · Disposition to issuer · Disposed 100,810 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each RSU subject to performance-based vesting conditions ("PSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such PSU (assuming attainment of (A) the actual level of performance for performance metrics for which the relevant performance period had been completed as of the Effective Time and (B) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period had not been completed as of the Effective Time) and (ii) the Merger Consideration. F5: (Continued from Footnote 4) The amount reported represents PSUs for which performance was deemed achieved assuming attainment of maximum level of performance.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports the disposition of securities pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 4, 2024, by and among the Issuer, Johnson & Johnson ("J&J"), and Sweep Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of the effective time of the Merger (the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. As a result of the Merger, at the Effective Time, each outstanding share of common stock, par value $0.001 per share, of the Issuer ("Common Stock") outstanding immediately prior to the Effective Time (excluding Excluded Shares and any Dissenting Company Shares, each as defined in the Merger Agreement) was automatically converted into the right to receive $335.00 in cash (the "Merger Consideration"),

F2: (Continued from Footnote 1) without interest and less any applicable withholding taxes. Additionally, pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time and (ii) the Merger Consideration.

F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price that was less than the Merger Consideration, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.

F4: Pursuant to the Merger Agreement, at the Effective Time, each RSU subject to performance-based vesting conditions ("PSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such PSU (assuming attainment of (A) the actual level of performance for performance metrics for which the relevant performance period had been completed as of the Effective Time and (B) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period had not been completed as of the Effective Time) and (ii) the Merger Consideration.

F5: (Continued from Footnote 4) The amount reported represents PSUs for which performance was deemed achieved assuming attainment of maximum level of performance.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 14, 2022 Filed Nov 16, 2022 20:03 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	7,998	$243.22	$1,945,273.56	Disclosure SEC source: 0001209191-22-057420 · doc4.xml · nonDerivative · entry 8 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,753 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F9 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $242.66 to $243.65. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
November 14, 2022 Filed Nov 16, 2022 20:03 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	2,710	$242.12	$656,145.20	Disclosure SEC source: 0001209191-22-057420 · doc4.xml · nonDerivative · entry 7 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,751 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F8 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $241.66 to $242.58. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
November 14, 2022 Filed Nov 16, 2022 20:03 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	5,941	$241.06	$1,432,137.46	Disclosure SEC source: 0001209191-22-057420 · doc4.xml · nonDerivative · entry 6 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,461 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F7 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $240.60 to $241.52. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
November 14, 2022 Filed Nov 16, 2022 20:03 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	1,482	$240.07	$355,783.74	Disclosure SEC source: 0001209191-22-057420 · doc4.xml · nonDerivative · entry 5 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,402 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F6 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $239.60 to $240.55. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
November 14, 2022 Filed Nov 16, 2022 20:03 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	2,780	$239.07	$664,614.60	Disclosure SEC source: 0001209191-22-057420 · doc4.xml · nonDerivative · entry 4 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,884 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F5 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $238.60 to $239.50. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
November 14, 2022 Filed Nov 16, 2022 20:03 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	2,642	$238.01	$628,822.42	Disclosure SEC source: 0001209191-22-057420 · doc4.xml · nonDerivative · entry 3 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,664 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F4 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $237.56 to $238.54. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
November 14, 2022 Filed Nov 16, 2022 20:03 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	3,720	$237.16	$882,235.20	Disclosure SEC source: 0001209191-22-057420 · doc4.xml · nonDerivative · entry 2 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,306 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F3 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $236.56 to $237.55. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
November 14, 2022 Filed Nov 16, 2022 20:03 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	900	$235.72	$212,148.00	Disclosure SEC source: 0001209191-22-057420 · doc4.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,026 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F2 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $235.30 to $236.07. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
November 14, 2022 Filed Dec 2, 2022 20:19 UTC Amendment	Shockwave Medical, Inc. SWAV · Entity 90374	Exercise / conversionStock Option · Derivative	30,000	$0.00 Strike: $3.42	$0.00	Disclosure SEC source: 0001209191-22-059519 · doc4a.xml · derivative · entry 2 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 394,799 Underlying: Common Stock · 30,000 shares Expires 2027-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F2 · derivative.exercise_date: Twenty-Five percent of the shares subject to this option vested on 5/9/18 and the balance of the shares vested in equal monthly installments. Read SEC document
November 14, 2022 Filed Dec 2, 2022 20:19 UTC Amendment	Shockwave Medical, Inc. SWAV · Entity 90374	Exercise / conversionCommon Stock	30,000	$3.42	$102,480.00	Disclosure SEC source: 0001209191-22-059519 · doc4a.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. Read SEC document
August 11, 2022 Filed Aug 12, 2022 20:32 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	200	$287.00	$57,400.00	Disclosure SEC source: 0001209191-22-045715 · doc4.xml · nonDerivative · entry 11 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,926 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F12 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $286.96 to $287.03. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
August 11, 2022 Filed Aug 12, 2022 20:32 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	400	$285.41	$114,164.00	Disclosure SEC source: 0001209191-22-045715 · doc4.xml · nonDerivative · entry 10 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,126 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F11 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $285.19 to $285.73. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
August 11, 2022 Filed Aug 12, 2022 20:32 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	1,900	$284.63	$540,797.00	Disclosure SEC source: 0001209191-22-045715 · doc4.xml · nonDerivative · entry 9 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,526 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F10 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $284.16 to $285.02. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
August 11, 2022 Filed Aug 12, 2022 20:32 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	1,016	$283.74	$288,279.84	Disclosure SEC source: 0001209191-22-045715 · doc4.xml · nonDerivative · entry 8 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,426 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F9 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $283.15 to $284.14. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
August 11, 2022 Filed Aug 12, 2022 20:32 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	2,503	$282.38	$706,797.14	Disclosure SEC source: 0001209191-22-045715 · doc4.xml · nonDerivative · entry 7 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,442 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F8 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $282.00 to $282.91. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
August 11, 2022 Filed Aug 12, 2022 20:32 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	6,586	$281.55	$1,854,288.30	Disclosure SEC source: 0001209191-22-045715 · doc4.xml · nonDerivative · entry 6 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,945 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F7 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $280.97 to $281.96. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
August 11, 2022 Filed Aug 12, 2022 20:32 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	5,987	$280.48	$1,679,233.76	Disclosure SEC source: 0001209191-22-045715 · doc4.xml · nonDerivative · entry 5 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,531 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F6 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $279.96 to $280.91. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
August 11, 2022 Filed Aug 12, 2022 20:32 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	3,741	$279.37	$1,045,123.17	Disclosure SEC source: 0001209191-22-045715 · doc4.xml · nonDerivative · entry 4 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,518 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F5 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $278.96 to $279.95. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
August 11, 2022 Filed Aug 12, 2022 20:32 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	5,116	$278.51	$1,424,857.16	Disclosure SEC source: 0001209191-22-045715 · doc4.xml · nonDerivative · entry 3 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,259 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F4 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $277.95 to $278.94. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
August 11, 2022 Filed Aug 12, 2022 20:32 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	1,751	$277.57	$486,025.07	Disclosure SEC source: 0001209191-22-045715 · doc4.xml · nonDerivative · entry 2 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,375 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F3 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $276.93 to $277.89. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
August 11, 2022 Filed Aug 12, 2022 20:32 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	800	$276.11	$220,888.00	Disclosure SEC source: 0001209191-22-045715 · doc4.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,126 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F2 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $275.80 to $276.78. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
August 11, 2022 Filed Dec 2, 2022 20:18 UTC Amendment	Shockwave Medical, Inc. SWAV · Entity 90374	Exercise / conversionStock Option · Derivative	30,000	$0.00 Strike: $3.42	$0.00	Disclosure SEC source: 0001209191-22-059518 · doc4a.xml · derivative · entry 2 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,799 Underlying: Common Stock · 30,000 shares Expires 2027-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F2 · derivative.exercise_date: Twenty-Five percent of the shares subject to this option vested on 5/9/18 and the balance of the shares vested in equal monthly installments. Read SEC document
August 11, 2022 Filed Dec 2, 2022 20:18 UTC Amendment	Shockwave Medical, Inc. SWAV · Entity 90374	Exercise / conversionCommon Stock	30,000	$3.42	$102,480.00	Disclosure SEC source: 0001209191-22-059518 · doc4a.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. Read SEC document
June 06, 2022 Filed Jun 8, 2022 20:24 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	Exercise / conversionStock Option · Derivative	7,400	$0.00 Strike: $3.42	$0.00	Disclosure SEC source: 0001209191-22-035259 · doc4.xml · derivative · entry 7 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 454,799 Underlying: Common Stock · 7,400 shares Expires 2027-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F7 · derivative.exercise_date: Twenty-Five percent of the shares subject to this option vested on 5/9/18 and the balance of the shares vested in equal monthly installments. Read SEC document
June 06, 2022 Filed Jun 8, 2022 20:24 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	34	$181.29	$6,163.86	Disclosure SEC source: 0001209191-22-035259 · doc4.xml · nonDerivative · entry 6 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,926 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F6 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $180.91 to $181.30. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
June 06, 2022 Filed Jun 8, 2022 20:24 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	66	$179.58	$11,852.28	Disclosure SEC source: 0001209191-22-035259 · doc4.xml · nonDerivative · entry 5 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,960 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F5 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $179.50 to $180.05. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
June 06, 2022 Filed Jun 8, 2022 20:24 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	14	$178.36	$2,497.04	Disclosure SEC source: 0001209191-22-035259 · doc4.xml · nonDerivative · entry 4 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,026 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F4 · price: All reported securities were sold at a price of $178.36. Read SEC document
June 06, 2022 Filed Jun 8, 2022 20:24 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	5,016	$177.53	$890,490.48	Disclosure SEC source: 0001209191-22-035259 · doc4.xml · nonDerivative · entry 3 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,040 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F3 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $177.14 to $177.97. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
June 06, 2022 Filed Jun 8, 2022 20:24 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	2,270	$176.73	$401,177.10	Disclosure SEC source: 0001209191-22-035259 · doc4.xml · nonDerivative · entry 2 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,056 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F2 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $176.13 to $177.12. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
June 06, 2022 Filed Jun 8, 2022 20:24 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	Exercise / conversionCommon Stock	7,400	$3.42	$25,278.40	Disclosure SEC source: 0001209191-22-035259 · doc4.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,326 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. Read SEC document
May 27, 2022 Filed Jun 1, 2022 19:01 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	Exercise / conversionStock Option · Derivative	2,600	$0.00 Strike: $3.42	$0.00	Disclosure SEC source: 0001209191-22-033301 · doc4.xml · derivative · entry 3 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 462,199 Underlying: Common Stock · 2,600 shares Expires 2027-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F3 · derivative.exercise_date: Twenty-Five percent of the shares subject to this option vested on 5/9/18 and the balance of the shares are scheduled to vest in equal monthly installments thereafter for 36 months. Read SEC document
May 27, 2022 Filed Jun 1, 2022 19:01 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	2,600	$175.06	$455,156.00	Disclosure SEC source: 0001209191-22-033301 · doc4.xml · nonDerivative · entry 2 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,926 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F2 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $175.00 to $175.26. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
May 27, 2022 Filed Jun 1, 2022 19:01 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	Exercise / conversionCommon Stock	2,600	$3.42	$8,881.60	Disclosure SEC source: 0001209191-22-033301 · doc4.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,526 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. Read SEC document
May 13, 2022 Filed May 13, 2022 20:19 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	Exercise / conversionStock Option · Derivative	5,000	$0.00 Strike: $3.42	$0.00	Disclosure SEC source: 0001209191-22-029012 · doc4.xml · derivative · entry 3 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 464,799 Underlying: Common Stock · 5,000 shares Expires 2027-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F3 · derivative.exercise_date: Twenty-Five percent of the shares subject to this option vested on 5/9/18 and the balance of the shares are scheduled to vest in equal monthly installments thereafter for 36 months. Read SEC document
May 13, 2022 Filed May 13, 2022 20:19 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	5,000	$150.00	$750,000.00	Disclosure SEC source: 0001209191-22-029012 · doc4.xml · nonDerivative · entry 2 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,926 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F2 · price: All reported securities were sold at a price of $150.00. Read SEC document
May 13, 2022 Filed May 13, 2022 20:19 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	Exercise / conversionCommon Stock	5,000	$3.42	$17,080.00	Disclosure SEC source: 0001209191-22-029012 · doc4.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. Read SEC document
May 11, 2022 Filed May 12, 2022 20:15 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	Exercise / conversionStock Option · Derivative	15,000	$0.00 Strike: $3.42	$0.00	Disclosure SEC source: 0001209191-22-028684 · doc4.xml · derivative · entry 15 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 469,799 Underlying: Common Stock · 15,000 shares Expires 2027-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F15 · derivative.exercise_date: Twenty-Five percent of the shares subject to this option vested on 5/9/18 and the balance of the shares are scheduled to vest in equal monthly installments thereafter for 36 months. Read SEC document
May 11, 2022 Filed May 12, 2022 20:15 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	700	$148.30	$103,810.00	Disclosure SEC source: 0001209191-22-028684 · doc4.xml · nonDerivative · entry 14 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,926 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F14 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $147.82 to $148.65. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
May 11, 2022 Filed May 12, 2022 20:15 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	700	$147.15	$103,005.00	Disclosure SEC source: 0001209191-22-028684 · doc4.xml · nonDerivative · entry 13 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,626 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F13 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $146.79 to $147.63. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
May 11, 2022 Filed May 12, 2022 20:15 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	1,400	$146.12	$204,568.00	Disclosure SEC source: 0001209191-22-028684 · doc4.xml · nonDerivative · entry 12 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,326 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F12 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $145.55 to $146.54. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
May 11, 2022 Filed May 12, 2022 20:15 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	1,500	$145.02	$217,530.00	Disclosure SEC source: 0001209191-22-028684 · doc4.xml · nonDerivative · entry 11 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,726 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F11 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $144.48 to $145.38. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
May 11, 2022 Filed May 12, 2022 20:15 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	500	$142.87	$71,435.00	Disclosure SEC source: 0001209191-22-028684 · doc4.xml · nonDerivative · entry 10 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,226 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F10 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $142.68 to $142.99. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
May 11, 2022 Filed May 12, 2022 20:15 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	300	$142.10	$42,630.00	Disclosure SEC source: 0001209191-22-028684 · doc4.xml · nonDerivative · entry 9 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,726 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F9 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $141.68 to $142.45 The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
May 11, 2022 Filed May 12, 2022 20:15 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	900	$140.84	$126,756.00	Disclosure SEC source: 0001209191-22-028684 · doc4.xml · nonDerivative · entry 8 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,026 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F8 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $140.61 to $141.45. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
May 11, 2022 Filed May 12, 2022 20:15 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	3,100	$140.03	$434,093.00	Disclosure SEC source: 0001209191-22-028684 · doc4.xml · nonDerivative · entry 7 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,926 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F7 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $139.55 to $140.49. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
May 11, 2022 Filed May 12, 2022 20:15 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	1,300	$139.00	$180,700.00	Disclosure SEC source: 0001209191-22-028684 · doc4.xml · nonDerivative · entry 6 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,026 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F6 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $138.48 to $139.45. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
May 11, 2022 Filed May 12, 2022 20:15 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	1,239	$137.62	$170,511.18	Disclosure SEC source: 0001209191-22-028684 · doc4.xml · nonDerivative · entry 5 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,326 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F5 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $137.38 to $138.19. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
May 11, 2022 Filed May 12, 2022 20:15 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	1,538	$136.84	$210,459.92	Disclosure SEC source: 0001209191-22-028684 · doc4.xml · nonDerivative · entry 4 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,565 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F4 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $136.35 to $137.32. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
May 11, 2022 Filed May 12, 2022 20:15 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	1,523	$136.09	$207,265.07	Disclosure SEC source: 0001209191-22-028684 · doc4.xml · nonDerivative · entry 3 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,103 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F3 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $135.35 to $136.33. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
May 11, 2022 Filed May 12, 2022 20:15 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	300	$134.28	$40,284.00	Disclosure SEC source: 0001209191-22-028684 · doc4.xml · nonDerivative · entry 2 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,626 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 2/27/2022. F2 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $134.03 to $134.77. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.